Researchers in Dubai are launching a pioneering 500-person study to determine if improving metabolic health can slow the progression of Alzheimer’s disease long before memory loss begins. By focusing on adults aged 55 and older who suffer from conditions like diabetes, obesity, or hypertension, the team—led by Metabolic in partnership with Roche—aims to monitor pTau217, a critical blood biomarker linked to Alzheimer’s-related brain changes. The goal is to see if intensive lifestyle interventions can lower these biomarker levels over a 12-month period, potentially offering a way to intervene decades before typical symptoms appear.

This study is particularly significant as it seeks to provide the first local data on the prevalence of pTau217 within the UAE. Participants will undergo regular monitoring during routine clinic visits, and those showing elevated levels will receive specialized care, including cardiology referrals and behavioral coaching to optimize their metabolic control. By integrating this biomarker into standard wellness protocols, researchers hope to prove that identifying and treating metabolic risks early can serve as a proactive strategy to reduce dementia risk, ultimately changing the clinical landscape for patients predisposed to neurodegenerative decline.